CY1118540T1 - Μονοκλωνικα αντισωματα - Google Patents
Μονοκλωνικα αντισωματαInfo
- Publication number
- CY1118540T1 CY1118540T1 CY20171100132T CY171100132T CY1118540T1 CY 1118540 T1 CY1118540 T1 CY 1118540T1 CY 20171100132 T CY20171100132 T CY 20171100132T CY 171100132 T CY171100132 T CY 171100132T CY 1118540 T1 CY1118540 T1 CY 1118540T1
- Authority
- CY
- Cyprus
- Prior art keywords
- fibrinogen
- fibrin
- region
- monoclonal antibodies
- vectors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Η παρούσα εφεύρεση παρέχει ένα απομονωμένο αντίσωμα που προσδένει μια περιοχή YC φιμπρίνης ή ινωδογόνου. Σε διάφορες απόψεις, το αντίσωμα αναστέλλει τη μικρογλοιακή προσκόλληση στην περιοχή yC φιμπρίνης ή ινωδογόνου, αναστέλλει την πρόσδεση του Mac-1 στην περιοχή yC φιμπρίνης ή ινωδογόνου, ή/και καταστέλλει τα κλινικά συμπτώματα της Πειραματικής Αυτοάνοσης Εγκεφαλομυελίτιδας (ΕΑΕ). Παρέχονται διάφορες μέθοδοι χρησιμοποίησης των αντισωμάτων, φαρμακευτικές συνθέσεις, κυτία, φορείς, κύτταρα που περιλαμβάνουν τους φορείς, και μέθοδοι δημιουργίας αντισωμάτων.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24801409P | 2009-10-02 | 2009-10-02 | |
| PCT/US2010/050873 WO2011041518A1 (en) | 2009-10-02 | 2010-09-30 | Monoclonal antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1118540T1 true CY1118540T1 (el) | 2017-07-12 |
Family
ID=43826649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171100132T CY1118540T1 (el) | 2009-10-02 | 2017-01-30 | Μονοκλωνικα αντισωματα |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US8877195B2 (el) |
| EP (1) | EP2483416B1 (el) |
| JP (1) | JP5883389B2 (el) |
| KR (1) | KR101793221B1 (el) |
| CN (1) | CN102575277B (el) |
| AR (1) | AR078490A1 (el) |
| AU (1) | AU2010300559B2 (el) |
| BR (1) | BR112012008370B8 (el) |
| CA (1) | CA2774256C (el) |
| CL (1) | CL2012000788A1 (el) |
| CO (1) | CO6440561A2 (el) |
| CR (1) | CR20120127A (el) |
| CY (1) | CY1118540T1 (el) |
| DK (1) | DK2483416T3 (el) |
| DO (1) | DOP2012000089A (el) |
| EA (1) | EA023477B1 (el) |
| ES (1) | ES2614939T3 (el) |
| GE (2) | GEP20156214B (el) |
| GT (1) | GT201200096A (el) |
| HK (1) | HK1168871A1 (el) |
| HR (1) | HRP20170110T1 (el) |
| HU (1) | HUE031571T2 (el) |
| IL (1) | IL218621B (el) |
| IN (1) | IN2012DN03154A (el) |
| LT (1) | LT2483416T (el) |
| MA (1) | MA33704B1 (el) |
| MX (1) | MX2012003811A (el) |
| MY (1) | MY159359A (el) |
| NZ (1) | NZ598770A (el) |
| PL (1) | PL2483416T3 (el) |
| PT (1) | PT2483416T (el) |
| SI (1) | SI2483416T1 (el) |
| SM (1) | SMT201700083B (el) |
| TN (1) | TN2012000149A1 (el) |
| TW (1) | TWI511741B (el) |
| UA (1) | UA108860C2 (el) |
| WO (1) | WO2011041518A1 (el) |
| ZA (1) | ZA201202227B (el) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8771693B2 (en) | 2009-10-27 | 2014-07-08 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the generation and use of conformation-specific antibodies |
| CN103702967A (zh) | 2011-03-14 | 2014-04-02 | 貝丝以色列女执事医疗中心 | 用于治疗增殖性病症的方法和组合物 |
| WO2012149334A2 (en) | 2011-04-27 | 2012-11-01 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the generation and use of conformation-specific antibodies |
| WO2012162698A1 (en) | 2011-05-26 | 2012-11-29 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the treatment of immune disorders |
| AU2013271378A1 (en) | 2012-06-07 | 2014-12-18 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the inhibition of Pin1 |
| JP6448614B2 (ja) | 2013-03-15 | 2019-01-09 | ベス イスラエル デアコネス メディカル センター インコーポレイテッド | コンフォメーション特異的抗体の発生および使用のための方法および組成物 |
| US10451611B2 (en) | 2014-01-11 | 2019-10-22 | The J. David Gladstone Institute | Compositions and methods for in vitro assays of fibrin activity |
| WO2016011268A1 (en) | 2014-07-17 | 2016-01-21 | Beth Israel Deaconess Medical Center, Inc. | Atra for modulating pin1 activity and stability |
| US10351914B2 (en) | 2014-07-17 | 2019-07-16 | Beth Israel Deaconess Medical Center, Inc. | Biomarkers for Pin1-associated disorders |
| WO2016145186A1 (en) | 2015-03-12 | 2016-09-15 | Beth Israel Deaconess Medical Center, Inc. | Enhanced atra-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions |
| SG11201910113PA (en) * | 2017-05-02 | 2019-11-28 | Nat Cancer Center Japan | Plasmin-cleavable anti-insoluble fibrin antibody-drug conjugate |
| KR20220161374A (ko) * | 2020-03-31 | 2022-12-06 | 국립연구개발법인 고쿠리츠간켄큐센터 | 피브린에 결합하는 항체 및 당해 항체를 포함하는 의약 조성물 |
| EP4262870A1 (en) * | 2020-12-16 | 2023-10-25 | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone | Use of fibrin-targeting immunotherapy to reduce coronavirus pathogenesis |
| WO2022159776A1 (en) * | 2021-01-21 | 2022-07-28 | Therini Bio, Inc. | Antibodies which bind human fibrin and methods of use |
| CN117794948A (zh) * | 2021-06-18 | 2024-03-29 | 特里尼生物公司 | 结合人纤维蛋白或纤维蛋白原γC结构域的抗体及其使用方法 |
| EP4355772A2 (en) * | 2021-06-18 | 2024-04-24 | Therini Bio, Inc. | Antibodies which bind human fibrin or fibrinogen ?c domain and methods of use |
| WO2024044583A1 (en) * | 2022-08-22 | 2024-02-29 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Human anti-fibrin antibodies and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030031675A1 (en) * | 2000-06-06 | 2003-02-13 | Mikesell Glen E. | B7-related nucleic acids and polypeptides useful for immunomodulation |
| PT2314620E (pt) * | 2004-05-27 | 2013-09-02 | Crucell Holland Bv | Método de identificação de moléculas de ligação capazes de neutralizar o vírus da raiva |
| US7807645B2 (en) * | 2005-09-23 | 2010-10-05 | The Regents Of The University Of California | Method of treating degenerative disorders of the nervous system by administration of fibrinogen fragment |
-
2010
- 2010-09-30 GE GEAP201012676A patent/GEP20156214B/en unknown
- 2010-09-30 SI SI201031390A patent/SI2483416T1/sl unknown
- 2010-09-30 AU AU2010300559A patent/AU2010300559B2/en active Active
- 2010-09-30 KR KR1020127011293A patent/KR101793221B1/ko active IP Right Grant
- 2010-09-30 ES ES10821238.2T patent/ES2614939T3/es active Active
- 2010-09-30 MY MYPI2012001408A patent/MY159359A/en unknown
- 2010-09-30 GE GEAP201013232A patent/GEP20166458B/en unknown
- 2010-09-30 HU HUE10821238A patent/HUE031571T2/en unknown
- 2010-09-30 DK DK10821238.2T patent/DK2483416T3/en active
- 2010-09-30 CN CN201080046037.8A patent/CN102575277B/zh active Active
- 2010-09-30 BR BR112012008370A patent/BR112012008370B8/pt active IP Right Grant
- 2010-09-30 UA UAA201203044A patent/UA108860C2/ru unknown
- 2010-09-30 NZ NZ598770A patent/NZ598770A/en unknown
- 2010-09-30 LT LTEP10821238.2T patent/LT2483416T/lt unknown
- 2010-09-30 EA EA201270416A patent/EA023477B1/ru unknown
- 2010-09-30 CA CA2774256A patent/CA2774256C/en active Active
- 2010-09-30 MX MX2012003811A patent/MX2012003811A/es active IP Right Grant
- 2010-09-30 JP JP2012532307A patent/JP5883389B2/ja active Active
- 2010-09-30 PL PL10821238T patent/PL2483416T3/pl unknown
- 2010-09-30 EP EP10821238.2A patent/EP2483416B1/en active Active
- 2010-09-30 WO PCT/US2010/050873 patent/WO2011041518A1/en active Application Filing
- 2010-09-30 PT PT108212382T patent/PT2483416T/pt unknown
- 2010-10-01 TW TW099133559A patent/TWI511741B/zh active
- 2010-10-01 AR ARP100103578A patent/AR078490A1/es not_active Application Discontinuation
-
2012
- 2012-03-14 IL IL218621A patent/IL218621B/en not_active IP Right Cessation
- 2012-03-16 CR CR20120127A patent/CR20120127A/es unknown
- 2012-03-20 US US13/425,020 patent/US8877195B2/en active Active
- 2012-03-27 ZA ZA2012/02227A patent/ZA201202227B/en unknown
- 2012-03-29 DO DO2012000089A patent/DOP2012000089A/es unknown
- 2012-03-30 TN TNP2012000149A patent/TN2012000149A1/en unknown
- 2012-03-30 CL CL2012000788A patent/CL2012000788A1/es unknown
- 2012-03-30 GT GT201200096A patent/GT201200096A/es unknown
- 2012-04-12 IN IN3154DEN2012 patent/IN2012DN03154A/en unknown
- 2012-04-18 CO CO12064155A patent/CO6440561A2/es active IP Right Grant
- 2012-04-30 MA MA34824A patent/MA33704B1/fr unknown
- 2012-09-27 HK HK12109512.6A patent/HK1168871A1/zh unknown
-
2017
- 2017-01-23 HR HRP20170110TT patent/HRP20170110T1/hr unknown
- 2017-01-30 CY CY20171100132T patent/CY1118540T1/el unknown
- 2017-02-08 SM SM201700083T patent/SMT201700083B/it unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1118540T1 (el) | Μονοκλωνικα αντισωματα | |
| CY1120414T1 (el) | Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους | |
| CY1118880T1 (el) | Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
| CY1120144T1 (el) | Αντισωματα αντι-n3pglu αμυλοειδους βητα πεπτιδιου και χρησεις αυτων | |
| WO2018098363A3 (en) | Mono- and bispecific antibodies binding to coagulation factor ix and coagulation factor x | |
| CY1116584T1 (el) | Ανθρωπινα αυτοαντισωματα αντι-αλφα-συνουκλεϊνης | |
| CY1118069T1 (el) | Αντισωματα anti-bcma | |
| CO6710903A2 (es) | Un anticuerpo que reconoce y se une específicamente con un fosfo-epítope en la proteína tau de mamífero o en uno de sus fragmentos y una composición comprendiendo el mismo | |
| CY1116488T1 (el) | Αντισωματα anti-προπερδινης | |
| CY1113089T1 (el) | Ανθρωπινα μονοκλωνικα αντισωματα σε ειδικο προστατικο μεμβρανικο αντιγονο (psma) | |
| ATE497508T1 (de) | Gegen das säugetier-eag1-ionenkanalprotein gerichtete antikörper | |
| EA201100527A1 (ru) | Биологические продукты | |
| EA200800953A1 (ru) | Человеческие моноклональные антитела к cd70 | |
| EA201291243A1 (ru) | Антитела против респираторно-синцитиального вируса (рсв) и способы их применения | |
| GT201200271A (es) | Proteínas que se unen al tnf-a | |
| BR112012006492A2 (pt) | proteína de fusão de anticorpo multivalente, e, ligação de albumina | |
| PE20220142A1 (es) | Anticuerpos de cadena pesada que se unen al psma | |
| MX353958B (es) | Proteinas de union al antigeno cd27l. | |
| CY1120803T1 (el) | Πρωτεϊνες δεσμευσης με αντιγονο ειδικες για το συστατικο ρ αμυλοειδους ορου | |
| CY1115960T1 (el) | Θεραπευτικη αγωγη ογκων χρησιμοποιωντας ειδικο αντισωμα anti-l1 | |
| AR065312A1 (es) | Nuevos anticuerpos | |
| CY1120448T1 (el) | Αντιγονοδεσμευτικες πρωτεϊνες σε ογκοστατινη μ (osm) | |
| EP4253959A3 (en) | Anti-idiotypic antibodies directed to the antigen-binding portion of an bcma-binding molecule | |
| BR112021020357A2 (pt) | Anticorpos anti-cd3 de alta afinidade e métodos para sua geração e uso | |
| JP2018507254A5 (el) |